1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-5 of 5 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2021Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancerLin, H.-M.; Huynh, K.; Kohli, M.; Tan, W.; Azad, A.A.; Yeung, N.; Mahon, K.L.; Mak, B.; Sutherland, P.D.; Shepherd, A.; Mellett, N.; Docanto, M.; Giles, C.; Centenera, M.M.; Butler, L.M.; Meikle, P.J.; Horvath, L.G.
2020Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibitionNassar, Z.D.; Mah, C.Y.; Centenera, M.M.; Irani, S.; Sadowski, M.C.; Scott, J.S.; Nguyen, E.V.; Nagarajan, S.R.; Moldovan, M.; Lynn, D.J.; Daly, R.J.; Hoy, A.J.; Butler, L.M.
2021ELOVL5 is a critical and targetable fatty acid elongase in prostate cancerCentenera, M.M.; Scott, J.S.; Machiels, J.; Nassar, Z.D.; Miller, D.C.; Zinonos, I.; Dehairs, J.; Burvenich, I.J.G.; Zadra, G.; Chetta, P.; Bango, C.; Evergren, E.; Ryan, N.K.; Gillis, J.L.; Mah, C.Y.; Tieu, T.; Hanson, A.R.; Carelli, R.; Bloch, K.; Panagopoulos, V.; et al.
2020Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)Scheinberg, T.; Kench, J.; Stockler, M.; Mahon, K.L.; Sebastian, L.; Stricker, P.; Joshua, A.M.; Woo, H.; Thanigasalam, R.; Ahmadi, N.; Centenera, M.M.; Butler, L.M.; Horvath, L.G.
2021A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growthGillis, J.L.; Hinneh, J.A.; Ryan, N.K.; Irani, S.; Moldovan, M.; Quek, L.-E.; Shrestha, R.; Hanson, A.R.; Xie, J.; Hoy, A.J.; Holst, J.; Centenera, M.M.; Mills, I.G.; Lynn, D.J.; Selth, L.A.; Butler, L.M.

Discover